STRYKER CORPSYK
STRYKER CORP Financial Overview 2021–2025
Updated Jul 10, 2026Stryker deployed nearly $5.0 billion in FY2025 to acquire Inari Medical, a strategic capital allocation that propelled its MedSurg and Neurotechnology segment to a 15.7% growth rate. This highlights a core investment thesis: Stryker’s relentless acquisition engine, paired with consistent unit volume expansion, provides the underlying pricing power necessary to overcome macroeconomic margin pressures.
The medical technology company has consistently scaled its operations, as revenue grew from $17.1 billion in FY2021 to $25.1 billion in FY2025. By the end of FY2025, gross margin expanded to 64.0%, yielding $4.89 billion in operating income and $5.04 billion in operating cash flow. While a global cybersecurity incident in Q1 2026 temporarily compressed gross margin to 63.3% due to supply chain and manufacturing disruptions, the company still managed to increase total net sales by 2.6% to $6.02 billion during the quarter. The market has heavily rewarded this combination of M&A execution and operational resilience. At the close of FY2025, the stock traded at $351.47, commanding a 41.8x P/E multiple against $8.40 in earnings per share.
Recent Developments (Q4 2025 and Q1 2026)
Stryker successfully resolved a disruptive IT breach in Q1 2026, fully restoring its global systems without altering full-year guidance. To streamline operations post-recovery, the company created a new Ortho Tech business unit combining orthopaedic instruments with Mako enabling technologies. First-quarter net earnings still jumped 13.9% year-over-year to $745 million, or $1.93 per share. The company also strengthened its balance sheet by repaying $1,000 million in senior unsecured notes.
Bulls are encouraged by the underlying 9.9% organic sales growth achieved in FY2025 alongside a steady $3.36 per share annual dividend. Conversely, bears point to the stagnating Orthopaedics segment, which managed a mere 0.1% growth to $2.81 billion in Q1 2026. Following a post-breach pullback, shares traded at a more modest 33.6x P/E as of the May 11, 2026 reporting date.
What to watch: margin recovery trajectory post-cyberattack; the September 2026 transition of Emily Baculik to Chief Accounting Officer.
Rev
$25.12B
FY2025
NI
$3.25B
FY2025
EPS
$8.49
FY2025
OCF
$5.04B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
STRYKER CORP 8-K Report, Corporate Update (Jun 26, 2026)
Stryker Corporation (SYK) has filed a Form 8-K to provide updated segment reporting information. This filing details a change in organizational structure initiated in the first quarter of 2026, which combines the orthopaedic instruments portfolio from its Instruments business with the Mako and enabling technologies portfolio from its Other Orthopaedics business to form a new 'Ortho Tech' business. This strategic move aims to simplify the customer experience and accelerate market speed through focused innovation. While this reorganization creates a new internal business unit, Stryker will continue to report its financial results under its two existing reportable segments: MedSurg and Neurotechnology, and Orthopaedics. The primary purpose of this 8-K is to comply with SEC regulations requiring the recasting of prior period financial statements in certain future filings (like registration statements or proxy statements) to reflect these segment changes. Investors should note that this filing does not restate previously issued financial statements or update the Management's Discussion and Analysis from the 2025 10-K, but provides recast information for the year ended December 31, 2025, as detailed in Exhibit 99.1.
STRYKER CORP 8-K Report, Executive Changes (May 20, 2026)
Stryker Corporation (SYK) announced a leadership transition in its accounting department, with Vice President and Chief Accounting Officer William E. Berry, Jr. retiring effective September 1, 2026. Emily Baculik, currently Vice President, Corporate Controller, will assume the role of Chief Accounting Officer starting the same date. This transition involves a planned advisory period for Mr. Berry and a compensation adjustment for Ms. Baculik as she steps into her new role. Investors should note the smooth handover facilitated by Mr. Berry's advisory role and the clear succession plan. Ms. Baculik brings extensive experience from various finance and accounting leadership positions within Stryker and other publicly traded companies. The filing details the terms of Mr. Berry's transition agreement, including continued salary and bonus eligibility, and Ms. Baculik's new compensation structure, which includes a base salary increase and potential long-term incentive awards.
STRYKER CORP 8-K Report, Shareholder Vote Results (May 8, 2026)
Stryker Corporation (SYK) filed an 8-K on May 8, 2026, reporting the results of its Annual Meeting of Shareholders held on May 6, 2026. The primary focus of the filing is the voting outcomes on three key proposals: the election of directors, the ratification of the independent registered public accounting firm, and an advisory vote on executive compensation. All proposals received substantial shareholder support, indicating a positive sentiment from the company's investors regarding its governance and financial oversight. Specifically, all ten nominated directors were overwhelmingly elected, demonstrating continued confidence in the company's leadership. Shareholders also ratified the appointment of Ernst & Young LLP as the independent auditor for 2026, a standard but important vote for financial transparency. Furthermore, the advisory resolution on executive compensation was approved, suggesting that shareholders are largely in agreement with the company's compensation practices for its named executive officers.
STRYKER CORP 8-K Report, Financial Results (Apr 30, 2026)
Stryker Corporation (SYK) has filed a Form 8-K on April 30, 2026, to report its first quarter 2026 operating results. The primary purpose of this filing is to provide investors with the company's financial performance and condition for the period ending March 31, 2026, as detailed in the accompanying press release (Exhibit 99.1). While this report itself is informational, the press release contains the substantive details of the company's Q1 2026 performance. Investors should refer to the press release, Exhibit 99.1, for specific financial metrics, revenue figures, profitability, and any forward-looking statements or guidance provided by Stryker management. The filing serves as the official mechanism to disseminate this critical quarterly update. It's important to note the disclaimer stating the information furnished is not deemed "filed" under Section 18 of the Exchange Act, meaning it's not subject to the same liabilities for misstatements or omissions as formally filed documents, though it is still material information.
STRYKER CORP 8-K/A Report, Cybersecurity Incident (Apr 9, 2026)
This 8-K/A filing from Stryker Corp. (SYK) provides an important update regarding a material cybersecurity incident first disclosed in March 2026. The company confirms that the incident, which occurred on March 11, 2026, caused disruptions to its business operations. While an investigation is ongoing with the help of third-party experts and law enforcement, Stryker has determined the incident had a material impact on its operations and, consequently, its financial results for the first quarter of 2026. Despite the Q1 financial impact, Stryker believes the incident is not reasonably likely to materially impact its full-year 2026 guidance. As of the filing date, the company has fully restored operations across its global manufacturing network, and its commercial, ordering, and distribution systems are back online. Investors should note that the company plans to discuss these financial results and guidance components in more detail during its Q1 2026 earnings report scheduled for April 30, 2026.
View all 8-K filings →